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Introduction
It is well known that chronic headache patients complain
of loss of concentration and memory disturbances and
often doctors as well as patients attribute this impairment
both to chronic pain and daily drug use.
Comorbidity between headache and other disorders
such as psychological or memory problems is a topic of
increasing scientific interest. A central neurogenic mecha-
nism such as a dysregulation of some neurotransmitter
system might underlie not only headache but also other
coexistent disorders; findings highlight the role of sero-
tonin pathways [1–3].
Savarese in 2000 evaluated the memory functions in
71 patients with chronic daily headache and showed a
severe impairment in patients with chronic tension-type
headache (CTTH), especially for visual-spatial memory,
without relation to drug abuse, and suggested a serotoner-
gic imbalance [4]. Afterwards, an abnormal cortical pro-
cessing of nociceptive input in chronic migraine patients
was suggested, which represents a typical chronic state of
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Abstract The objective of this
study was to establish if chronic
headaches with medication overuse
can modify a topo-kinesthetic
memory test. Nineteen patients with
medication overuse headache
(MOH), 13 patients with chronic
tension-type headache (CTTH)
without medication use and a group
of “normal” subjects underwent a
topo-kinesthetic memory test at T0
and after one month (T1); a control
group of healthy volunteers was
also tested to establish the baseline
in our experimental setting. After
one month, in the MOH patients
there was a reduction of medication
overuse from 3.3±2.65 to 1.1±2.23
(p<0.01), but no significant reduc-
tion in headache frequency and
severity index, quality of life, anxi-
ety and depression scores. The nav-
igation time at T0 was 14.3±4.97,
27.9±10.12, 34.3±15.38 and
7.5±2.33, 10.1±2.95, 11.4±3.21 for
control, MOH and CTTH with
closed and open eyes, respectively
(p<0.02). At T1, the MOH patients
reached performances with open
eyes similar to the healthy controls,
while with closed eyes the naviga-
tion test reached times similar to
those of CTTH patients. The topo-
kinesthetic memory test seems both
able to discriminate MOH and
CTTH from healthy volunteers and
to be related to pain scores but is
not influenced by the use of drugs.
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pain. In both tension-type headache and chronic migraine
groups, and in the case of episodic migraine, an inability
to reduce pain elaboration during an alternative cognitive
task emerged as an abnormal behaviour probably predis-
posing to migraine [5].
A recent cohort population-based study on the long-
term effects of migraine on cognitive function showed that
cognitive tests in twins with migraine or one of the
migraine subtypes did not differ from those of non-
migraineurs in any of the tests [6]. This reassuring study
should not be considered as conclusive, as illustrated by
the editorial [7] which accompanied the article, taking
into account that evidence was provided that migraineurs,
particularly those with aura, have an increased likelihood
of abnormalities in the MRI signal in the cerebellar terri-
tory of the posterior circulation and, for women, in the
deep white matter [8]. These finding are suggestive of an
overlapping of areas involved in aura origin in regions
with MRI signal abnormalities, so that many investigators
concluded that these signals represent sequelae of
ischaemia [9].
In conclusion, the commentary concluded that, in the
future, studies will need to account for other categories of
migraine and also to perform tests exploring visual-spatial
and visual-perceptual organisation and processing [10].
The functions related to visual-spatial performances
involve a number of cognitive strategies, and several
types of reference frames can be used by the brain to
establish relations between our body and the environment.
In humans, the parietal and frontal structures involved in
“spatial neglect”, and a parietal-temporal lobe network,
involved in the cortical processing of vestibular informa-
tion, have also been found to be involved in the egocentric
orientation tasks of subjective midline detection and in
visual-spatial memory during tasks in which subjects had
to mentally remember a path by mental navigation or
mental scanning of a map (“topo-kinetic” or “topo-kines-
thetic” memory) [11].
It should be noted that dizziness and memory impair-
ment can be induced by many drugs, such as antidepres-
sants, especially TCA, benzodiazepines, muscle relaxants,
beta-blockers and anti-convulsant drugs. Also NSAIDs,
such as indomethacin, have vertigo as a common side
effect, and triptans too can induce central disturbances
such as somnolence and dizziness.
It was reasonable to study patients with CTTH and
with chronic analgesic overuse who often complain of
loss of memory and subjective equilibrium impairment.
Because impairment of memory was reported in the past
as a proper symptom in chronic headache with and with-
out drug abuse, with a relevant impact on functional dis-
ability, we decided to use a topo-kinesthetic memory test,
which has been used in the rehabilitation of dizzy patients,
to evaluate the ability of patients with chronic headache to
perform a complex test using memory as vestibular and
proprioceptive capacities [12].
The aim of this test was to establish if the disturbances
of equilibrium and memory often complained of by
patients with chronic headache were related to the time
spent in a standard navigation, and to evaluate a new test
aimed at exploring topo-kinesthetic memory in patients
with chronic headache with and without medication drug
overuse.
Patients and methods
Subjects
During the period 1 January 2004 through 30 June 2004, 36 con-
secutive patients coming to the Modena Headache Study Center
were enrolled: 17 patients suffered from CTTH and 19 from
medication overuse headache (MOH) diagnosed following the
International Classification of Headache Disorders-2 (ICHD-2)
criteria [12]. Moreover, 14 healthy volunteers free from
migraine or vestibular disorders underwent the same protocol.
Study design
This was an open, non-controlled, non-randomised trial aimed at
recording the responses of patients with chronic headache with
and without daily drug use.
Patients were admitted to the Modena University Study
Center and enrolled in this study after fulfilling the criteria for
the diagnosis of MOH or CTTH by the ICHD-2 [13].
A control group of healthy volunteers matched for sex and age
was also tested to obtain a reference parameter with respect to the
patients in our experimental setting. In fact, this topo-kinesthetic
test has been used only in restricted settings, and widespread
accepted reference values have not been established [12].
All human studies were committed and performed in accor-
dance with the ethical standards of the 1964 Declaration of
Helsinki. All patients and healthy volunteers gave their informed
consent prior to their inclusion in the study.
At baseline, T0, patients were measured for headache and
quality-of-life (QoL) parameters. Then, patients with MOH were
treated with a standard protocol for these patients aimed at with-
drawing the medication overuse by changing the analgesic drug
and starting a new prophylactic treatment [14].
Patients with CTTH followed their previous treatment and
were retested after one month.
The navigation test was performed in the Audio-Vestibular
Center of Modena University.
Navigation test (walking on memorised course test)
The technique is aimed at strengthening spatial analysis and
memorising abilities. It is based on the ability to memorise
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vestibular and proprioceptive inputs, and to convert them into
information regarding the space-time coordinates of the various
moves covered [15].
The patient is requested to visually observe and memorise a
certain course, painted on a grey carpet with a smooth surface that
cannot be perceived by the feet, which can be a simple square, tri-
angle or a circle. The patient walks along the course the first time
with closed eyes, then he repeats the exercise two times with open
eyes and tries again with closed eyes. The exercise is performed in
one direction. Patients performed the exercise barefoot. The time
needed to complete the test was recorded for every exercise.
The technique involves many central cortical functions.
During step 1 (closed eyes) the patients rely exclusively on the
cortex’s spatial memorising abilities. In the following steps with
open eyes, the patients gain more sensorial inputs, and in the last
test we explore the rapid learning for navigational strategy.
Patient evaluation
Patients were administered the Zung Anxiety and Depression
scales, a QoL questionnaire and a test to evaluate the overall
pain influence on performances as described by Von Korff, the
Headache Severity Score [16].
Headache severity
Headache severity (HS) can be described according to Von Korff
[14] with the following six HS grades: Grade 0, free of
headaches for 6 months; Grade 1, low interference, low intensi-
ty; Grade 2A, low interference, high intensity; Grade 2B, medi-
um interference, high intensity; Grade 3, high interference, mod-
erately limiting; Grade 4, high interference, severely limiting.
Quality of life
In 1998 Jhingran developed a 16-item Migraine-Specific
Quality-of-Life Questionnaire (MSQ) (Version 2.0) to assess the
effect of migraine and its treatment on patients’ health-related
quality of life (HR-QOL). The MSQ was hypothesised to mea-
sure 3 meaningful dimensions: (i) Role Function-Restrictive; (ii)
Role Function-Preventive; and (iii) Emotional Function. Results
supported the existence of 3 distinct factors that agreed strongly
with the hypothesised dimensions [17]. The analysis of post-
treatment data suggested that the underlying factor structure of
the MSQ varies as a result of treatment. In this study we used
this questionnaire.
Statistical analysis
Appropriate statistical analyses were carried out both for intra-
group evaluation (paired t-test) and for group comparisons
(ANOVA, t-test and Wilcoxon test).
Results
The demographic data of the patients and the healthy vol-
unteers did not show significant differences between
groups and controls with respect to age and sex, as report-
ed in Table 1.
The clinical characteristics of headaches are report-
ed in Table 2, and are grouped as HS, as explained
above, medication overuse, number of analgesics taken
every observed day and the Headache Index (HI), indi-
cating the number of days with headache in an observed
period. The data referring to the values of HS, HI and
Medication Overuse were recorded at time T0 and after
one month.
The psychological status and the self-evaluation of
QoL were recorded for the patients at time T0 and after
one month (T1). The values of Zung’s scales for anxiety
and depression and the results of the QoL test are sum-
marised in Table 3.
To outline all possible alterations in learning and per-
forming the scheduled navigation test, we submitted the
patients and volunteers to all the geometric figures at time
T0 and T1. In Table 4 the times needed to navigate the tri-
angle both with open eyes and with closed eyes in the first
and second test are reported.
In Tables 5 and 6 the times spent to navigate the circle
and square, respectively, both with open and closed eyes
in the first and second test are reported.
Finally, in Table 7 the performances obtained in the tri-
angle with open and closed eyes at T0, i.e., during the
maximum drug use period, in MOH patients divided with
regard to the overused drugs (grouped by pharmacological
classes) are reported.
Table 1 Demographic data. Data are mean±SD unless otherwise
indicated
Controls MOH CTTH
Sex, n
M 4 3 4
F 10 16 13
Age, years 50.8±15.16 56.5±10.35 51.8±17.99
Table 2 Evaluation of headache characteristics. Data are mean±SD
TEST MOH CTTH
Time (T0) HS 4.7±0.99* 4.2±1.52
MO 3.3±2.65* 0,02±0.01
HI 0.87±0.21* 0.9±0.45
Time (T1) HS 4.3±1.37* 3.8±1.22
MO 1.1±2.23* 0.01±0.01
HI 0.72±0.35* 0.8±0.73
HS, Headache Severity; MO, medication overuse (number of anal-
gesic medications/observed days); HI, Headache Index (number of
headache days/observed days)
*p<0.01, T1 vs. T0 (t-paired test)
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Table 3 Patients’ status evaluation. Data are mean±SD
Zung A Zung D MSQ
T0 T1 T0 T1 T0 T1
Controls 30.8±6.85* 29.7±7.21* 29.6±6.33* 27.8±6.85* 15.57±3.62* 16.32±4.3*
MOH 47.3±9.58* 45.7±10.08* 46.4±11.47* 44.6±9.48* 51.8±11.62* 46.4±14.80*
CTTH 44.5±6.98* 45.1±7.12* 47.2±8.42* 47.5±9.35* 46±8.34* 45.9±5.78*
*p<0.05 vs. all patient’s values (t-test)
There were no differences between the T0 and T1 tests for both groups of patients, or between MOH and CTTH
Table 4 Navigation test: triangle. Data are mean±SD
Closed eyes 1 Closed eyes 2 Open eyes
Controls 14.3±4.97*§ 11.8±4.62° 7.5±2.33°
MOH T0 27.9±10.12*§ 21.1±10.12° 10.1±2.95°
MOH T1 20.4±8.01*§ 15.9±5.66° 8.8±2.73°
CTTH T0 34.3±15.38§* 23.4±9.54° 11.4±3.21°
CTTH T1 34.1±13.63§* 21.6±8.86° 11.1±2.89°
ANOVA and Wilcoxon test p<0.05 vs. controls out of (°)
*t-test p<0.002 (T0 vs. T1)
§t-test p<0.05 (test 1 vs. test 2)
Table 5 Navigation test: circle. Data are mean±SD
Closed eyes 1 Closed eyes 2 Open eyes
Controls 14.7±4.71*§ 10.6±3.19° 7.2±1.97°
MOH T0 30.3±11.41*§ 20.0±6.74° 10.0±2.91°
MOH T1 20.5±10.57*°. 15.6±6.29° 8.8±2.67°
CTTH T0 27.1±11.19§* 20.8±10.23° 12.4±5.27°
CTTH T1 24.7±12.90*§ 20.5±7.85° 11.9±4.60°
ANOVA and Wilcoxon test p<0.05 vs. controls out of (°)
*t-test, p<0.002 (T0 vs. T1)
§t-test, p<0.05 (test 1 vs. test 2)
Table 6 Navigation test: square. Data are mean±SD
Closed eyes 1 Closed eyes 2 Open eyes
Controls 18.7±4.19*§ 15.5±4.68*° 10.0±2.78°
MOH T0 38.1±10.76*§ 28.3±9.49*° 13.2±4.06°
MOH T1 27.9±10.20*§ 22.3±9.34°* 12.3±4.38°
CTTH T0 36.4±13.26*§ 28.2±12.11*° 15.8±5.27°
CTTH T1 36.5±13.83*§ 29.4±12.60*° 16.0±4.96°
ANOVA and Wilcoxon test p<0.05 vs. controls out of (°)
*t-test p<0.002 (T0 vs. T1)
§t-test p<0.05 (test 1 vs. test 2)
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Discussion
The population data confirm that the three groups were
comparable for age and sex.
It is difficult to assess the clinical features of migraine
and state objective and measurable parameters to fulfil the
classification criteria because migraine ranges in severity,
with mild headache and no disability on one extreme to
excruciating pain and complete disability on the other.
Because of this spectrum of severity, diagnosis alone does
not provide enough information to permit the selection of
optimal therapy. A headache grading system might help
headache sufferers and clinicians match the therapy not
only to the diagnosis but also to the overall severity of ill-
ness; such a system provides the best hope for cost-effec-
tive health care interventions [18]. Therefore, a measur-
able test could improve the capacity of grading the sever-
ity scores of headache patients and aid in improving and
monitoring therapeutic strategies.
At time T0 the HS scores were similar in both CTTH
and MOH patients, and even if the HS was slightly
reduced in MOH patients, this difference did not reach
statistical significance.
After one month, analgesic use was significantly
reduced in the MOH group, whereas this aspect did not
modify the overall evaluation recorded by the HS score.
This aspect is reasonable because the overall evaluation of
the HS implies a larger time period.
The anxiety and depression scales were significantly
higher compared with normal subjects, but did not differ
between the two patient groups at time T0 or after one month.
Similar data were reported by the QoL MSQ scale. It
was noticeable that QoL started to improve for MOH
patients reducing drug overuse but, probably due to the
short follow-up and the small sample, there were no sig-
nificant differences in the total QoL analysis.
The final evaluation of the QoL score was identical in
MOH and CTTH patients. This point is noticeable because
it suggests that medication overuse could be a mechanism to
reach an acceptable QoL even in the case of daily headache.
In Table 4 the times employed by our patients to per-
form the navigation test in the triangle shape are reported;
considering that we found similar values in the circle and
square navigation we will discuss only the triangle navi-
gation data.
The open-eyes tests were significantly different at T0
(p<0.02, t-test) both for MOH and CTTH patients vs. con-
trols. One month later, the reduction in drug overuse
reduced the time of the navigation, so that MOH patients
performed the test in a time not different from the “nor-
mal” standard, whereas the difference with CTTH was
maintained (p<0.02).
The loss of differences between MOH and controls in
the open-eyes test after the drug overuse reduction repre-
sents the only parameters that change concomitantly with
drug overuse withdrawal. It seems to be related to motor
performance: this test does not involve memory processes
and the patients need only to pay attention to the walking
navigation. In this way we can suppose that the test shows
that the reduction of drug overuse seems to increase the
capacity to carefully perform motor exercises.
The closed-eyes test is characterised by a reduction in
walking time due to the learning in the second test
(p<0.01, t-paired, both at T0 and T1). At T0 there were
significant differences between controls and patients
(p<0.002). After drug reduction both MOH and CTTH
patients maintained significant differences compared with
controls (p<0.03 and 0.001, respectively). The differences
between patient groups were not significant at T0, where-
as they reached a significant difference at T1, suggesting
an improvement of performances in the MOH group
(p<0.01, t-test). This difference was maintained also in the
second test at T1.
Tests performed with triangle course (Tables 5 and 6)
did not add any further information.
The analysis of the navigation test with respect to the
overused drugs did not show significant differences,
probably due to the small sample. During the first test
with closed eyes at T0 it was interesting to note that both
NSAIDs and mixtures impaired the triangle test, while
triptans did not. The data seem to suggest that triptans
Table 7 Performances in navigation test (triangle) grouped for overused drugs. Data are mean±SD unless otherwise indicated
Drug n Open eyes Closed eyes 1
NSAIDs 6 10.5±2.95 29.2±7.49*
Triptans 5 8.1±2.34 22.4±4.13$
Mixtures# 8 10.4±3.13 23.8±12.56*
Controls 12 7.5±2.33 14.3±4.97$
#NSAIDs plus caffeine and almobarbital or chlorpromazine
ANOVA for all groups p=0.005
p<0.05 (t-test) vs. controls
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are the drugs that least impair walking ability and mem-
ory. This fact could be surprising when compared with
the fact that barbiturates and phenothiazines did not alter
the performances significantly more than simple
NSAIDs. These data need to be confirmed in larger
patient samples.
On the other hand, we are aware that the sample size is
insufficient to draw significant or definitive conclusions
with respect to single drugs, and the data we showed only
suggested the possibility that there are differences due to
this variable.
Conclusions
First of all, in this study we observed that MOH patients
responded well in reducing drug overuse by following a
standard protocol to treat overuser patients [19, 20]. In
this series the HI did not change significantly because
almost all patients continued to complain of near daily
headache. Even though the total number of days with
headache was reduced by 17%, the HS test was not able to
detect an improvement because of the short observational
time. The only data suggesting a clinical improvement
was the significant reduction in daily analgesic use, which
suggests a reduction in daily HS.
On the other hand, the patients suffering from CTTH
were shown to be subjects who tended to lead their own
lives in the presence of a near daily headache, with a “tol-
erable” pain, and they had experienced in the past that
drugs were useless to reduce their headache, so they did
not use analgesics.
In both groups the QoL did not differ significantly
either at T0 or after discontinuation of therapy. This point
seems to be interesting in order to discuss the significance
of daily drug use that does not fulfil the typical criteria of
drug abuse, such as compulsive seeking behaviour and
withdrawal syndrome, and could suggest avoiding the
classification of these patients as “abusers” or addicts
because of their daily analgesic use.
Also, the self-evaluation tests for anxiety and depres-
sion were similar in both groups and the drug reduction
did not change this parameter. Even this evaluation was
limited by the brevity of the follow-up period.
The QoL of overusers slightly improved after one
month, but without reaching statistical significance
(p=0.32, t-test), suggesting that these patients feel little
difference even if they reduce drug intake. In this setting
analgesic drug use should be considered as only one of the
elements in patients suffering from MOH.
Both groups showed an impressive delay in navigating
the figures, with little or no differences with regard to the
shape (triangle, circle or square).
Navigation with closed eyes was performed in a time
that was double that of normal subjects and the second
probe with closed eyes at T0 reduced the navigation times
proportionally as in controls (ANOVA=NS, 1 vs. 2). This
observation suggests that patients learn like controls, but
were slower to navigate the figures. In fact, in the open-
eyes test the differences between patients and controls
were significant at T0.
This data could suggest that drug overuse can reduce
navigation speed, so that the attention to navigate with
open eyes seems to be restored after analgesic overuse
reduction and the slight improvement in clinical status
leads these patients to normal performances. Otherwise,
the CTTH performances did not differ significantly from
MOH patients, confirming the stable condition of these
patients. We have to consider that these results need to be
confirmed with larger series to establish the significance
of these differences.
In conclusion, these data suggest that this navigation
test seems to be well related to the HI and the HS in
patients suffering from chronic headaches. The test seems
more strictly related to the QoL and the pain of patients
than their drug use. This point is really interesting because
doctors and patients often attribute the loss or impairment
of memory to drug use. The test examines the topo-kinet-
ic memory and the ability to memorise and actuate a spa-
tial activity that implies the use of visual and vestibular-
spatial memory and muscle activity.
These results suggest that this test could be useful to
study patients with a mild loss of operational memory or
complying difficulties in practical activities.
These data need to be validated in larger clinical settings.
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